Cardiac troponin I predicts clinical outcome of patients with cancer at emergency department

Background The prognostic ability of cardiac troponin I (TnI) has been demonstrated in general populations and among cardiovascular disease patients, but it has not been evaluated in cancer patients. Hypothesis This study assumes to have the prognostic ability of cardiac troponin in cancer patients...

Full description

Saved in:
Bibliographic Details
Published in:Clinical cardiology (Mahwah, N.J.) N.J.), 2020-12, Vol.43 (12), p.1585-1591
Main Authors: Park, Soo Hyun, Kim, Taerim, Cha, Won Cul, Yoon, Hee, Hwang, Sung Yeon, Shin, Tae Gun, Sim, Min Seob, Jo, IkJoon, Lee, Seung‐Hwa, Park, Hyung‐Doo, Choi, Jin‐Ho
Format: Article
Language:English
Subjects:
Aged
Angina pectoris
biomarker
Biomarkers
Biomarkers - blood
Blood cancer
Blood pressure
Cancer
cardiac troponin
Cardiovascular disease
Cardiovascular Diseases - blood
Cardiovascular Diseases - complications
Clinical Investigations
Clinical outcomes
Coronary vessels
Dyspnea
Electrocardiography
emergency departments
Emergency Service, Hospital - statistics & numerical data
Female
Follow-Up Studies
Heart attacks
Hospitals
Humans
Laboratories
Male
Medical imaging
Middle Aged
Neoplasms - complications
Pain
Prognosis
Retrospective Studies
Risk Factors
Troponin I - blood
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background The prognostic ability of cardiac troponin I (TnI) has been demonstrated in general populations and among cardiovascular disease patients, but it has not been evaluated in cancer patients. Hypothesis This study assumes to have the prognostic ability of cardiac troponin in cancer patients visiting the emergency department. Methods Cancer patients visiting the emergency department were enrolled in this retrospective cohort study. Patients with previously known coronary artery disease or clinically indicated coronary angiography were not included. The maximal value from Siemens ADVIA Centaur troponin I Ultra assay within 24 hours was assessed. The primary endpoint was 180‐day all‐cause death, including cardiovascular and noncardiovascular death. Results A total of 9135 cancer patients (mean age: 63 years, male gender: 60%) were enrolled. Lowest (0.006 ng/mL), assay‐specific
ISSN:0160-9289
1932-8737
DOI:10.1002/clc.23486